GlassScriptPhysician profile
Beth L Booker
NPI 1609920891
$890.99
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $872 · 2022: $19.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $167.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.04 | 2021 | |
| Lilly USA, LLC | $132.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.76 | 2021 | |
| Amgen INC. | $50.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $47.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.48 | 2021 | |
| Merck Sharp & Dohme LLC | $43.57 | 2021 | |
| Novo Nordisk INC | $31.41 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.86 | 2021 | |
| Amarin Pharma, INC. | $22.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.05 | 2021 | |
| Esperion Therapeutics, INC. | $16.35 | 2021 | |
| Pfizer INC. | $14.65 | 2021 | |
| Adlon Therapeutics L.P. | $14.58 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $12.39 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Booker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.